Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Howard A. Burris, Daniel D. Von Hoff, Malcolm J. Moore et al.|Journal of Clinical Oncology|1997Cited by 5.9k
Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue CoalitionGregory A. Curt, Nicholas J. Vogelzang, Susan L. Scherr et al.|The Oncologist|2000Cited by 1.3k
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.Nicholas J. Vogelzang, Russell K. Portenoy, William Breitbart et al.|PubMed|1997Cited by 771
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerMace L. Rothenberg, Daniel D. Von Hoff, Malcolm J. Moore et al.|Annals of Oncology|1996Cited by 569